NextCell to present at the INNODIA Symposium during EASD 2026

September 28, 2026

NextCell Pharma AB (publ) (“NextCell” or the “Company”) has been invited to present its clinical development programme in type 1 diabetes at the INNODIA Symposium on T1D Therapies, held in connection with the European Association for the Study of Diabetes (EASD) 2026 meeting in Milan on 28 September. The presentation will focus on NextCell’s clinical programme for NXTCL-T1D, including long-term data from adult patients showing preservation of endogenous insulin production for more than six years following a single infusion.

INNODIA is a European network bringing together researchers, clinicians and drug developers in the field of type 1 diabetes. NextCell’s CEO, Mathias Svahn, will present during the conference’s cell therapy session.

The published conference material states that NextCell will present topline results from the ProTrans-Young study. The study is sponsored by Uppsala University, and NextCell has not yet received access to the study data. Therefore, no results from ProTrans-Young will be presented at the conference. The results will be presented separately once they become available.

“It is valuable for NextCell to present our programme in this setting alongside other leading organisations working in type 1 diabetes. We will focus on the clinical data currently available to us and on the continued development of NXTCL-T1D,” says Mathias Svahn, CEO of NextCell Pharma.

For more information, please contact:
Mathias Svahn, CEO
Eric Gustafsson, CFO
Tel: +46 (0)8-735 55 95
E-mail: info@nextcellpharma.com
Website:: www.nextcellpharma.com
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma

Certified Adviser
The company's shares are listed on the Nasdaq First North Growth Market.
RedEye Nordic Growth AB is the company´s Certified Adviser.

About NextCell Pharma AB
NextCell is a clinical-stage cell therapy company developing the proprietary NXTCL™ platform for the treatment of immune-mediated diseases, with a primary candidate in type 1 diabetes. NXTCL is designed to enable allogeneic cell therapies with controlled immunomodulation, consistent potency and scalable manufacturing. The company’s lead program in type 1 diabetes has shown potential to preserve insulin production and slow disease progression for several years after a single treatment. The group also includes the wholly owned subsidiaries NextCell Sverige, NextCell Hong Kong, Cellaviva and QVance. The company was founded in 2014 and is headquartered in Huddinge next to the Karolinska University Hospital.

Download attachment Read full press release on Cision (external link)

2023-08-08

ProTrans and NextCell gain international attention

Results from Professor Per-Ola Carlsson, Principal Investigator for NextCell’s Phase-I/II study with ProTrans stromal cells for Type 1 Diabetes are now published and featured in the Up-front section of the current issue of Diabetologia. The article was selected by the Editor as worthy of special attention, for its high quality and interest to the diabetes field. Furthermore, the article has already been cited in an International scientific journal.

Read more Read more

2023-07-27

NextCell publishes its Interim Report 3 2022/2023

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 3 for the period March 1, 2023 – May 31, 2023 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

Read more Read more

2023-07-05

Treatment start of severe pneumonia with high dose of ProTrans

NextCell Pharma AB ("NextCell" or the "Company") announces that the clinical trial ProTrans 19+SE (also called Protrans V) can start recruiting patients in the high dose group, which is the last dose group. Three patients treated with medium dose of ProTrans have been clinically evaluated and the data has been reviewed by the Data Safety Monitoring Board, which now allows continued treatment with high-dose ProTrans for severe pneumonia caused by COVID-19, Influenza, Human Metapneumovirus and RSV.

Read more Read more

2023-05-30

NextCell invited presenter at International Society for Cell and Gene Therapy meeting in Paris

NextCell Pharma AB's ("NextCell" or the"Company") CSO, Dr Lindsay Davies, has been invited to give a poster presentation at the ISCT meeting in Paris, showcasing NextCell´s long-term follow-up data from their phase II type I diabetes study with investigative medicinal product, ProTrans.

Read more Read more

2023-04-27

NextCell publishes its Interim Report 2 2022/2023

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period December 1, 2022 – February 28, 2023 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

Read more Read more

2023-04-26

Breakthrough multiplication of blood stem cells

NextCell Pharma AB (“NextCell” or the “company") announces that the FDA has approved a product of multiplied stem cells from umbilical cord blood. It is a breakthrough that could lead to increased interest in saving stem cells for private use, where Cellaviva is the market leader in Scandinavia. Cellaviva is a part of NextCell with offices in Stockholm and Copenhagen.

Read more Read more

2023-04-18

NextCell invited speaker at European Wound Management Association Meeting in Milan

NextCell Pharma AB´s ("NextCell" or the "Company") CSO, Dr Lindsay Davies, has been invited to give a presentation at the EWMA meeting in Milan, showcasing NextCell´s phase II clinical data with their investigative medicinal product, ProTrans, in slowing the progression of type-1 diabetes.

Read more Read more

2023-03-28

NextCell´s publication of the phase I/II clinical trial in type I diabetes accepted

NextCell Pharma AB (”NextCell” or ”Company”) have had their article detailing the results of their phase I/II clinical trial in type I diabetes accepted in the peer-reviewed journal Diabetologia.

Read more Read more